| | |
African-American
|
European-American
| |
---|
Gene
|
SNP
|
Genotype
|
Cases/Controls
|
OR (95% CI)
|
P
trend
|
Cases/Controls
|
OR (95% CI)
|
P
trend
|
P
interaction
|
---|
VDR
|
rs10783218
|
GG
|
178/304
|
1.00
|
0.82
|
194/352
|
1.00
|
0.04
|
0.04
|
| |
GA/AA
|
85/150
|
0.96 (0.69-1.34)
| |
20/17
|
2.05 (1.02-4.12)
| | |
VDR
|
rs3819545
|
AA
|
71/242
|
1.00
|
0.04
|
22/162
|
1.00
|
0.38
|
0.04
|
| |
AG
|
45/168
|
0.91 (0.59-1.40)
| |
26/156
|
1.22 (0.66-2.26)
| | |
| |
GG
|
3/43
|
0.23 (0.07-0.77)
| |
11/52
|
1.40 (0.62-3.15)
| | |
CYP24A1
|
rs927650
|
GG
|
66/258
|
1.00
|
0.62
|
10/116
|
1.00
|
0.003
|
0.10
|
| |
GA
|
47/170
|
1.09 (0.71-1.68)
| |
29/186
|
1.76 (0.81-3.78)
| | |
| |
AA
|
8/27
|
1.18 (0.50-2.79)
| |
20/68
|
3.46 (1.50-7.96)
| | |
CYP24A1
|
rs1570669
|
GG
|
15/81
|
1.00
|
0.69
|
32/158
|
1.00
|
0.03
|
0.05
|
| |
GA
|
69/219
|
1.77 (0.94-3.31)
| |
24/162
|
0.71 (0.40-1.27)
| | |
| |
AA
|
37/154
|
1.36 (0.69-2.67)
| |
3/50
|
0.28 (0.08-0.97)
| | |
CYP24A1
|
rs2209314
|
AA
|
102/393
|
1.00
|
0.33
|
46/208
|
1.00
|
0.004
|
0.003
|
| |
AG/GG
|
19/61
|
1.34 (0.74-2.40)
| |
13/162
|
0.38 (0.20-0.73)
| | |
CYP24A1
|
rs3787555
|
CC
|
79/326
|
1.00
|
0.02
|
25/175
|
1.00
|
0.91
|
0.09
|
| |
CA
|
37/122
|
1.42 (0.90-2.24)
| |
29/155
|
1.25 (0.69-2.24)
| | |
| |
AA
|
5/7
|
3.79 (1.11-12.91)
| |
5/38
|
0.83 (0.30-2.35)
| | |
CYP24A1
|
rs2762941
|
AA
|
16/120
|
1.00
|
0.004
|
24/132
|
1.00
|
0.54
|
0.05
|
| |
AG
|
61/212
|
1.97 (1.07-3.61)
| |
26/168
|
0.89 (0.49-1.65)
| | |
| |
GG
|
44/122
|
2.62 (1.38-4.98)
| |
9/68
|
0.78 (0.34-1.78)
| | |
CYP24A1
|
rs4809959
|
GG
|
32/133
|
1.00
|
0.99
|
14/131
|
1.00
|
0.01
|
0.07
|
| |
GA
|
64/223
|
1.13 (0.70-1.83)
| |
26/172
|
1.43 (0.71-2.88)
| | |
| |
AA
|
25/98
|
0.98 (0.54-1.78)
| |
19/66
|
2.71 (1.25-5.86)
| | |
CYP24A1
|
rs2585428
|
GG
|
27/109
|
1.00
|
0.65
|
26/90
|
1.00
|
0.006
|
0.02
|
| |
GA
|
66/246
|
1.12 (0.67-1.87)
| |
22/175
|
0.46 (0.24-0.87)
| | |
| |
AA
|
28/100
|
1.15 (0.63-2.10)
| |
11/105
|
0.36 (0.17-0.79)
| | |
- Odds ratio (OR) and 95% confidence interval (CI) are adjusted for covariates, including age, proportion of European ancestry, body mass index, family history of breast cancer, and education. Ptrend was for genetic dose response by coding genotypes as 0, 1, and 2 on the basis of the number of variant alleles. Pinteraction was for the differences in ORs between African-American and European-American women, and a Pinteraction of less than 0.10 was deemed significant. SNP, single-nucleotide polymorphism.